Drybench Patent.
SOFOSBUVIR; VELPATASVIR, NDA 208341
The patents and exclusivities FDA's Orange Book lists for NDA 208341 as captured on 14 October 2026, each date named by its rule and its rows, and any rows of FDA's Paragraph IV list captured on 17 October 2026 that give this NDA's number. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 19 Mar 2027 to 30 Jul 2034, each by its own rule; no one date stands for this product.
- Earliest listed date
- 19 Mar 2027ODE-293 exclusivityRule R3 · Products 001, 002
Source lines
exclusivity.txt lines 703, 705
- Latest listed date
- 30 Jul 2034US 9,757,406 with pediatric exclusivity, as listedRule R2 · Products 001, 002
Source lines
patent.txt lines 8,511, 8,541
- Latest substance patent
- 16 May 2033US 8,940,718 with pediatric exclusivity, as listedRule R2 · Products 001, 002
Source lines
patent.txt lines 8,505, 8,535
- Latest listed patent
- 30 Jul 2034US 9,757,406 with pediatric exclusivity, as listedRule R2 · Products 001, 002
Source lines
patent.txt lines 8,511, 8,541
- Latest exclusivity
- 19 Sep 2027PED exclusivityRule R3 · Products 001, 002
Source lines
exclusivity.txt lines 704, 706
Listed dates of other NDAs in the same years:20272028202920302031203220332034
28 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 208341, as listed. The sections below name products by these numbers.
Product 001 · EPCLUSA
- Dosage form; route
- TABLET;
ORAL - Strength
- 400MG;100MG
- Approval date as listed
- 28 Jun 2016
- Type as listed
- RX
- Applicant as listed
- GILEAD SCIENCES INC
Product 002 · EPCLUSA
- Dosage form; route
- TABLET;
ORAL - Strength
- 200MG;50MG
- Approval date as listed
- 19 Mar 2020
- Type as listed
- RX
- Applicant as listed
- GILEAD SCIENCES INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
30 entries from 60 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 8,334,270, substance and product and use patent
patent.txt lines 8,490, 8,520- Expiry as listed
- 21 Mar 2028
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,580,765, substance and product and use patent
patent.txt lines 8,494, 8,524- Expiry as listed
- 21 Mar 2028
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,735,372, use patent
patent.txt lines 8,500, 8,530- Expiry as listed
- 21 Mar 2028
- Rule
- R1
- Flags
- use code U-1470
- Product numbers
- 001, 002
US 9,085,573, substance and product and use patent
patent.txt lines 8,508, 8,538- Expiry as listed
- 21 Mar 2028
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,334,270 with pediatric exclusivity, as listed
patent.txt lines 8,489, 8,519- Expiry as listed
- 21 Sep 2028
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,580,765 with pediatric exclusivity, as listed
patent.txt lines 8,493, 8,523- Expiry as listed
- 21 Sep 2028
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,735,372 with pediatric exclusivity, as listed
patent.txt lines 8,499, 8,529- Expiry as listed
- 21 Sep 2028
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 9,085,573 with pediatric exclusivity, as listed
patent.txt lines 8,507, 8,537- Expiry as listed
- 21 Sep 2028
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 7,964,580, substance and product and use patent
patent.txt lines 8,488, 8,518- Expiry as listed
- 26 Mar 2029
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,633,309, substance and product and use patent
patent.txt lines 8,498, 8,528- Expiry as listed
- 26 Mar 2029
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,889,159, product and use patent
patent.txt lines 8,502, 8,532- Expiry as listed
- 26 Mar 2029
- Rule
- R1
- Flags
- product · use code U-1470
- Product numbers
- 001, 002
US 7,964,580 with pediatric exclusivity, as listed
patent.txt lines 8,487, 8,517- Expiry as listed
- 26 Sep 2029
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,633,309 with pediatric exclusivity, as listed
patent.txt lines 8,497, 8,527- Expiry as listed
- 26 Sep 2029
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,889,159 with pediatric exclusivity, as listed
patent.txt lines 8,501, 8,531- Expiry as listed
- 26 Sep 2029
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 9,284,342, substance and product and use patent
patent.txt lines 8,510, 8,540- Expiry as listed
- 13 Sep 2030
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,618,076, substance and product and use patent
patent.txt lines 8,496, 8,526- Expiry as listed
- 11 Dec 2030
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 9,284,342 with pediatric exclusivity, as listed
patent.txt lines 8,509, 8,539- Expiry as listed
- 13 Mar 2031
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,618,076 with pediatric exclusivity, as listed
patent.txt lines 8,495, 8,525- Expiry as listed
- 11 Jun 2031
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,575,135, substance and product and use patent
patent.txt lines 8,492, 8,522- Expiry as listed
- 16 Nov 2032
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,921,341, substance and product and use patent
patent.txt lines 8,504, 8,534- Expiry as listed
- 16 Nov 2032
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,940,718, substance and product and use patent
patent.txt lines 8,506, 8,536- Expiry as listed
- 16 Nov 2032
- Rule
- R1
- Flags
- substance · product · use code U-1470
- Product numbers
- 001, 002
US 8,575,135 with pediatric exclusivity, as listed
patent.txt lines 8,491, 8,521- Expiry as listed
- 16 May 2033
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,921,341 with pediatric exclusivity, as listed
patent.txt lines 8,503, 8,533- Expiry as listed
- 16 May 2033
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,940,718 with pediatric exclusivity, as listed
patent.txt lines 8,505, 8,535- Expiry as listed
- 16 May 2033
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 10,086,011, use patent
patent.txt lines 8,484, 8,514- Expiry as listed
- 30 Jan 2034
- Rule
- R1
- Flags
- use code U-1470
- Product numbers
- 001, 002
US 11,116,783, product and use patent
patent.txt lines 8,486, 8,516- Expiry as listed
- 30 Jan 2034
- Rule
- R1
- Flags
- product · use code U-1470
- Product numbers
- 001, 002
US 9,757,406, product patent
patent.txt lines 8,512, 8,542- Expiry as listed
- 30 Jan 2034
- Rule
- R1
- Flags
- product
- Product numbers
- 001, 002
US 10,086,011 with pediatric exclusivity, as listed
patent.txt lines 8,483, 8,513- Expiry as listed
- 30 Jul 2034
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 11,116,783 with pediatric exclusivity, as listed
patent.txt lines 8,485, 8,515- Expiry as listed
- 30 Jul 2034
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 9,757,406 with pediatric exclusivity, as listed
patent.txt lines 8,511, 8,541- Expiry as listed
- 30 Jul 2034
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
Listed exclusivities
Each exclusivity FDA lists for NDA 208341, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
ODE-293 exclusivity
exclusivity.txt lines 703, 705- Date
- 19 Mar 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001, 002
PED exclusivity
exclusivity.txt lines 704, 706- Date
- 19 Sep 2027
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001, 002
Paragraph IV list rows giving NDA 208341
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 208341, each cell as listed.
Rows with no NDA number this page can match are kept apart on the list page; some may concern this product.
No row of the Paragraph IV list captured on 17 October 2026 gives NDA 208341 in its RLD/NDA cell. This does not mean no certification was submitted or that no application challenges a patent listed here.
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week